Prohost Biotechnology
   
   
Biotechnology Research and Investment
   
     
Thursday Jul 3, 2008
Search
 
 
Prohost is ranked #1 from among 355 publications.
Some of our topics include:
Stem Cells
Genomics
Biotech industry news
Nanotechnology
FDA Approvals
Stock Performance
Breakthroughs in science.
M&As
Clinical trials - phase by phase.
...and much more

 

 
Welcome
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the headlines. However, selecting the biotechnology firms in which to invest requires not only an understanding of the company's finances, but also a knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
 
Biotech News and Comments
 
SOME NEWS 06/30/2008
 
HE SAID, SHE SAID, THEY SAID 06/27/2008
You will always hear a lot of opposing and challenging opinions, not only on Vanda’s sleeping pill tasimelteon, but on each and every drug following the announcement of results from clinical trials. The truth is ....
 
VANDA AGAIN? 06/27/2008
What do we think?
 
GOOD NEWS IN A BAD MARKET 06/26/2008
Another bad market day, which makes us expect some profit taking from the firms that have been recently in rallying moods. There is good news, but the bad bear will not let their news boost their stocks. The good news, though, must be remembered for future consideration.
 
WHAT'S NEW FOR TYPE 1 DIABETES 06/25/2008
Developing a treatment that could halt progression of type 1 diabetes and preserve enough islet cell function to avoid the need for insulin administration all together is the ultimate goal of endocrinologists.
 
 
 
Latest News Posted to subscribers
 
PROHOST E-LETTER # 272
The best in each Biotechnology discipline
PROHOST TABLE
For Issue #125 Part 2
PROHOST N-LETTER #125 PART TWO
PROHOST N-LETTER #125
ASCO
PROHOST E-LETTER # 271
Hype and opportunities. Cancer vaccine firms. Biotechnology near-term outperforming firms.
 
 
 
 
 
 
 
Member Area
Username
password
Forgot password?
click here
Reports For Sale
 
 
 
 
 
 
 
 
Home | Stocks | News and Comments | Subscribe now | About Us | Login